These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 8420443)

  • 1. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients.
    McDonald GB; Hinds MS; Fisher LD; Schoch HG; Wolford JL; Banaji M; Hardin BJ; Shulman HM; Clift RA
    Ann Intern Med; 1993 Feb; 118(4):255-67. PubMed ID: 8420443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.
    Carreras E; Bertz H; Arcese W; Vernant JP; Tomás JF; Hagglund H; Bandini G; Esperou H; Russell J; de la Rubia J; Di Girolamo G; Demuynck H; Hartmann O; Clausen J; Ruutu T; Leblond V; Iriondo A; Bosi A; Ben-Bassat I; Koza V; Gratwohl A; Apperley JF
    Blood; 1998 Nov; 92(10):3599-604. PubMed ID: 9808553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
    Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
    Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.
    Shulman HM; Hinterberger W
    Bone Marrow Transplant; 1992 Sep; 10(3):197-214. PubMed ID: 1422475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation.
    Sullivan KM; Kansu E; Storer B; Jocom J; Emerson G; Reagan T; Emerson V; Siadak MF; Davis C; Appelbaum FR; Buckner CD; Hansen JA; Shulman HM; Storb R; McDonald GB
    Biol Blood Marrow Transplant; 1998; 4(1):20-6. PubMed ID: 9701388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia.
    Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM
    Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis.
    Styler MJ; Crilley P; Biggs J; Moul J; Copelan E; Topolsky D; Avalos B; Penza S; Sabol P; Downs K; Szer J; Brodsky I; Marks DI
    Bone Marrow Transplant; 1996 Jul; 18(1):171-6. PubMed ID: 8832011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation.
    Bearman SI; Anderson GL; Mori M; Hinds MS; Shulman HM; McDonald GB
    J Clin Oncol; 1993 Sep; 11(9):1729-36. PubMed ID: 8355040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
    Cesaro S; Pillon M; Talenti E; Toffolutti T; Calore E; Tridello G; Strugo L; Destro R; Gazzola MV; Varotto S; Errigo G; Carli M; Zanesco L; Messina C
    Haematologica; 2005 Oct; 90(10):1396-404. PubMed ID: 16219577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
    Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
    Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation.
    Matute-Bello G; McDonald GD; Hinds MS; Schoch HG; Crawford SW
    Bone Marrow Transplant; 1998 Jun; 21(11):1125-30. PubMed ID: 9645575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.
    Brugieres L; Hartmann O; Benhamou E; Zafrani ES; Caillaud JM; Patte C; Kalifa C; Flamant F; Lemerle J
    Bone Marrow Transplant; 1988 Jan; 3(1):53-8. PubMed ID: 3048471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation.
    Bunin N; Leahey A; Dunn S
    Transplantation; 1996 Feb; 61(4):664-6. PubMed ID: 8610401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation.
    Hägglund H; Remberger M; Klaesson S; Lönnqvist B; Ljungman P; Ringdén O
    Blood; 1998 Dec; 92(12):4568-72. PubMed ID: 9845522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation.
    El-Sayed MH; El-Haddad A; Fahmy OA; Salama II; Mahmoud HK
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1347-54. PubMed ID: 15618844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institution.
    Kami M; Mori S; Tanikawa S; Akiyama H; Onozawa Y; Tanaka T; Okamoto R; Maeda Y; Sasaki T; Kaku H; Matsuura Y; Hiruma K; Sakamaki H
    Bone Marrow Transplant; 1997 Sep; 20(5):397-402. PubMed ID: 9339756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophosphamide preparative regimen.
    Brodsky R; Topolsky D; Crilley P; Bulova S; Brodsky I
    Am J Clin Oncol; 1990 Jun; 13(3):221-5. PubMed ID: 2346127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.